Yahoo!   My Yahoo!   Mail  
Search   
Sign In
New User? Sign Up
Home > Investing > ACHN > Summary

Achillion Pharmaceuticals, Inc.
(ACHN)

2.37USD   Down 0.05 (2.07%)   
At 2:30AM IST
 Achillion Pharmaceuticals, Inc. (NGM:ACHN) Delayed quote data 
[Chart]
1d  5d  3m  6m  1y  2y  5y 
Last Trade: 2.37USD
Trade Time:2:30AM IST
Change:Down 0.05 (2.07%) 
Prev Close:2.42
Open:2.46
Bid:2.28 x 500
Ask:2.54 x 500
1y Target Est:6.40
Day's Range:2.32 - 2.51
52wk Range:1.10 - 3.89
Volume:344,536
Avg Vol (3m):706,902
Market Cap:63.17M
P/E (ttm):N/A
EPS (ttm):-1.05
Div & Yield:N/A (N/A%)
Add ACHN to Portfolio   Download Data

HEADLINES

 
•Achillion to Present at 12th Annual BIO CEO and Investor Conference - GlobeNewswire  - Tue 2:30AM
•China Biotech Week in Review: New Investments in Life Science - Seeking Alpha  - Mon, Feb 8
•Achillion Pharma Out-Licensed China Rights for HIV, Hepatitis Treatment - Seeking Alpha  - Thu, Feb 4
•ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits - EDGAR Online  - Wed, Feb 3
•Ann Taylor, Lexmark, Achillion Pharma big movers - AP  - Wed, Feb 3
•Achillion Announces Closing of Underwriters' Over-Allotment Option - GlobeNewswire  - Wed, Feb 3
•Movers roundup: Rudolph Technologies, Hologic - AP  - Wed, Feb 3
•ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial - EDGAR Online  - Wed, Feb 3
•Achillion rises on hepatitis/HIV drug pact - AP  - Tue, Feb 2
•Achillion shares rise on drug development deal in China - Reuters  - Tue, Feb 2
•Achillion Pharma upgraded by Wedbush Morgan - Briefing.com  - Tue, Feb 2
•Achillion Announces License Agreement for Elvucitabine Development in China - GlobeNewswire  - Tue, Feb 2
» More Headlines for ACHN...

ANALYST

 
EPS Est (next year) (Dec-09) :-0.94
EPS Est (in 2 years) (Dec-10) :-0.60
Avg Rec (current)*:2.0
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
» Analyst Opinion» Estimates

BUSINESS SUMMARY

 
Achillion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for infectious diseases.

» Full Company Profile